Cliff Asness’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$86.9M Sell
695,432
-469,371
-40% -$61.8M 0.03% 648
2026
Q1
$162M Sell
1,164,803
-1,530,141
-57% -$214M 0.07% 354
2025
Q4
$331M Buy
2,694,944
+315,398
+13% +$38.3M 0.17% 135
2025
Q3
$264M Sell
2,379,546
-91,292
-4% -$10.4M 0.17% 149
2025
Q2
$272M Buy
2,470,838
+606,168
+33% +$64.5M 0.23% 96
2025
Q1
$207M Buy
1,864,670
+51,116
+3% +$5.27M 0.21% 107
2024
Q4
$168M Sell
1,813,554
-129,518
-7% -$11.7M 0.22% 101
2024
Q3
$163M Sell
1,943,072
-110,001
-5% -$8.39M 0.22% 95
2024
Q2
$141M Sell
2,053,073
-1,261,631
-38% -$84.2M 0.22% 106
2024
Q1
$243M Sell
3,314,704
-549,472
-14% -$42.3M 0.41% 38
2023
Q4
$313M Sell
3,864,176
-909,512
-19% -$70.8M 0.59% 20
2023
Q3
$358M Buy
4,773,688
+531,314
+13% +$40.9M 0.74% 12
2023
Q2
$325M Buy
4,242,374
+731,362
+21% +$58.3M 0.69% 14
2023
Q1
$287M Sell
3,511,012
-259,147
-7% -$21.5M 0.63% 19
2022
Q4
$322M Sell
3,770,159
-1,743,093
-32% -$138M 0.73% 15
2022
Q3
$340M Sell
5,513,252
-582,541
-10% -$36.7M 0.83% 11
2022
Q2
$376M Buy
6,095,793
+3,383,767
+125% +$209M 0.85% 8
2022
Q1
$161M Buy
2,712,026
+1,482,141
+121% +$94.7M 0.31% 62
2021
Q4
$89.3M Buy
1,229,885
+92,279
+8% +$6.36M 0.16% 144
2021
Q3
$79.5M Sell
1,137,606
-18,824
-2% -$1.32M 0.15% 163
2021
Q2
$79M Sell
1,156,430
-814,483
-41% -$54.4M 0.14% 175
2021
Q1
$127M Sell
1,970,913
-1,000,300
-34% -$64.5M 0.21% 115
2020
Q4
$169M Sell
2,971,213
-786,288
-21% -$47.4M 0.3% 70
2020
Q3
$235M Sell
3,757,501
-903,477
-19% -$62.7M 0.4% 48
2020
Q2
$353M Sell
4,660,978
-1,136,461
-20% -$87.1M 0.57% 25
2020
Q1
$433M Sell
5,797,439
-1,411,277
-20% -$97.5M 0.73% 18
2019
Q4
$465M Buy
7,208,716
+2,682,046
+59% +$175M 0.53% 33
2019
Q3
$287M Sell
4,526,670
-891,623
-16% -$58.3M 0.34% 77
2019
Q2
$363M Sell
5,418,293
-3,538,186
-40% -$233M 0.41% 49
2019
Q1
$582M Buy
8,956,479
+285,954
+3% +$19M 0.62% 22
2018
Q4
$542M Buy
8,670,525
+326,298
+4% +$22.8M 0.63% 29
2018
Q3
$644M Sell
8,344,227
-545,884
-6% -$41.2M 0.62% 31
2018
Q2
$630M Sell
8,890,111
-1,763,758
-17% -$125M 0.63% 28
2018
Q1
$803M Sell
10,653,869
-1,978,920
-16% -$157M 0.87% 11
2017
Q4
$905M Buy
12,632,789
+516,486
+4% +$39.2M 0.95% 6
2017
Q3
$982M Buy
12,116,303
+3,384,623
+39% +$259M 1.17% 3
2017
Q2
$618M Buy
8,731,680
+3,518,634
+67% +$234M 0.82% 8
2017
Q1
$354M Buy
5,213,046
+1,066,172
+26% +$75M 0.47% 38
2016
Q4
$297M Sell
4,146,874
-13,985
-0.3% -$1.04M 0.41% 52
2016
Q3
$329M Buy
4,160,859
+1,310,117
+46% +$106M 0.5% 30
2016
Q2
$238M Sell
2,850,742
-140,407
-5% -$12.5M 0.42% 44
2016
Q1
$275M Sell
2,991,149
-977,184
-25% -$88.1M 0.49% 30
2015
Q4
$402M Sell
3,968,333
-800,138
-17% -$83.3M 0.7% 12
2015
Q3
$468M Buy
4,768,471
+586,783
+14% +$65.2M 0.94% 5
2015
Q2
$490M Buy
4,181,688
+67,030
+2% +$7.32M 0.97% 5
2015
Q1
$404M Sell
4,114,658
-716,746
-15% -$72.8M 0.92% 6
2014
Q4
$455M Buy
4,831,404
+2,569,921
+114% +$266M 0.95% 3
2014
Q3
$241M Buy
2,261,483
+1,292,298
+133% +$127M 0.66% 16
2014
Q2
$80.4M Sell
969,185
-388,000
-29% -$30.2M 0.22% 122
2014
Q1
$96.2M Buy
1,357,185
+439,427
+48% +$34.5M 0.29% 77
2013
Q4
$69M Buy
917,758
+447,607
+95% +$31.2M 0.21% 126
2013
Q3
$29.5M Sell
470,151
-143,586
-23% -$8.58M 0.1% 246
2013
Q2
$31.4M Buy
+613,737
New +$32M 0.11% 234

Other funds holding GILD

Cliff Asness's GILD Position: Q2 2026 in Review

Cliff Asness reduced its Gilead Sciences (GILD) stake by 40% in Q2 2026, selling an estimated $61.8M and leaving 695,432 shares worth $86.9M. The position accounts for 0.03% of the portfolio, ranked #648.

Cliff Asness first reported a position in GILD in Q2 2013 and has held it in 53 quarters since. The position peaked at $982M in Q3 2017. 2,265 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Cliff Asness held 695,432 shares of Gilead Sciences worth $86.9M as of Q2 2026.
  • Cliff Asness sold 469,371 Gilead Sciences shares in Q2 2026, an estimated $61.8M.
  • Gilead Sciences made up 0.03% of Cliff Asness's portfolio in Q2 2026, its #648 holding.
  • Cliff Asness first reported a position in Gilead Sciences in Q2 2013 and has held it in 53 quarters since.
  • Cliff Asness's Gilead Sciences position peaked at $982M in Q3 2017.
  • 2,265 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.